Sabiia Seb
PortuguêsEspañolEnglish
Embrapa
        Busca avançada

Botão Atualizar


Botão Atualizar

Ordenar por: 

RelevânciaAutorTítuloAnoImprime registros no formato resumido
Registros recuperados: 2
Primeira ... 1 ... Última
Imagem não selecionada

Imprime registro no formato completo
Recent developments in biotech industry outside of the USA and Western Europe: Report from BIO 2005 Electron. J. Biotechnol.
Bourinbaiar,Aldar S..
The BIO 2005 international convention is the largest gathering of the biotech industry in the world. This year it was held on June 19-22 inside the behemoth Convention Center in downtown Philadelphia, bringing together 18,730 executives, investors, consultants, lawyers, politicians, scientists, and dreamers from 56 countries. More than 500 media representatives covered the event. Biotechnology research and findings presented by countries outside the USA and Western Europe has begun to make a significant impact on these annual BIO gatherings. The achievements of some of these countries are briefly reviewed.
Tipo: Journal article Palavras-chave: Africa; Asia; Bioindustry; Biotech; Biodefense; Eastern Europe; Latin America; Pacific; Russia.
Ano: 2006 URL: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-34582006000200002
Imagem não selecionada

Imprime registro no formato completo
Normalization of elevated liver enzymes due to V-1 Immunitor therapy Electron. J. Biotechnol.
Jirathitikal,Vichai; Metadilogkul,Orapun; Bourinbaiar,Aldar S..
V-1 Immunitor (V1) is an oral AIDS vaccine currently being used as a therapeutic modality by HIV-positive patients. Upon interim analysis of phase I safety trial it has been discovered that patients who had elevated liver enzymes aspartate (AST/SGOT) and alanine (ALT/SGPT) aminotransferases have experienced the reduction of enzyme levels back to normal. Two other hepatitis markers alkaline phosphatase and bilirubin have also decreased. V1’s effect may be hepatitis-specific since liver enzymes in normal patients treated with V1 have not changed and three patients who were Hepatitis B antigen positive at baseline became negative after therapy. The results suggest that V1 supplementation reduces hepatic damage caused by hepatitis viral infection.
Tipo: Journal article
Ano: 2003 URL: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-34582003000100010
Registros recuperados: 2
Primeira ... 1 ... Última
 

Empresa Brasileira de Pesquisa Agropecuária - Embrapa
Todos os direitos reservados, conforme Lei n° 9.610
Política de Privacidade
Área restrita

Embrapa
Parque Estação Biológica - PqEB s/n°
Brasília, DF - Brasil - CEP 70770-901
Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco

Valid HTML 4.01 Transitional